Hyperbaric Oxygen and Target Carboplatin Chemoradiotherapy for T4 Oral Cancer
| Project/Area Number |
16592035
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | University of Occupational and Environmental Health, Japan |
|---|
Principal Investigator |
OYA Ryoichi (2006) University of Occupational and Environmental Health, Japan, School of Medicine, Associate Professor, 医学部, 助教授 (70194313)
池村 邦男 (2004-2005) 産業医科大学, 医学部, 教授 (90038894)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGAHARA Toshio Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Professor, 大学院医歯学総合研究科, 教授 (10116048)
UEYAMA Yoshiya Yamaguchi University, School of Medicine, Professor, 医学部, 教授 (00168668)
SUGIHARA Kazumasa Kagoshima University, Graduate School of Medical and Dental Sciences, Professor, 大学院医歯学総合研究科, 教授 (00117516)
SUNAKAWA Hazime University of the Ryukyus, Faculty of Medicine, Professor, 医学部, 教授 (30112452)
HAMAKAWA Hiroyuki Ehime University School of Medicine, Faculty of Medicine, Professor, 医学部, 教授 (20127905)
大矢 亮一 産業医科大学, 医学部, 助教授 (70194313)
|
|---|
| Project Period (FY) |
2004 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 2006: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2005: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2004: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | multi-institutional clinical study / T4 oral and orppharyngeal tumor / squamous cell carcinoma / chemoradiotherapy / intra-arterial infusion / carboplatin / HBO therapy / hyperfractionated irradiation / T4 oral and orpharyngeal tumor / hyperfractionated irrdiation |
|---|
| Research Abstract |
Introduction Applying a new combined approach of hyperbaric oxygen (HBO) to target carboplatin chemoradiotherapy twelve T4 oral SCC patients have been treated since April 2000. HBO has been expected to enhance of effect to hypoxic cell fraction resistant to radiotherapy and/or chemotherapy within tumor. Tumor was radiated within twenty minutes after HBO dive. Material and Methods Twelve patients with histologically-proven, untreated squamous cell cancer of the oral cavity were enrolled. All tumors were classified as T4 according to UICC system, including four node-positive and eight negative tumors. One course of chemoradiotherapy consists of 30Gy hyperfractionated radiation, Intra-arterial carboplatin infused superselectively through angiographically placed catheter via femoral artery and daily oral tegafur-uracil (UFT【○!R】, 400-600 mg/day). Carboplatin dosage was determined on Calvert's formula (AUC=4.5). Among twice a day radiation second one was given within twenty minutes after HB
… More
O dive. After completion of one course of target chemoradiotherapy, surgery was planned principally as a subsequent therapy. When a patient refused surgical resection of the tumor, a second course was administered. Results and Conclusions Three tumors were resected after one course of the chemoradiotherapy, nine tumors were followed after two courses without surgery. Carboplatin dosage was 300-600mg, median 470mg, radiation dose was 30-102Gy, median 60Gy. All three histological specimen of resected tumors showed no residence of cancer cells. Among nine tumors treated only by chemoradiotherapy three tumors recurred at primary site, and two were salvaged successfully. During a median follow-up period of 16 months (4-53 months) eleven of twelve tumors were loco-regionally controlled. Two patients died of intercurrent disease, and 2-year disease-specific survival was 82 percent. A new concurrent use of hyperbaric oxygen with target chemoradiotherpy could provide a good loco-regional control, and improve survival of oral cancer patients with organ preservation. Less
|
Report
(4 results)
Research Products
(3 results)
